@Article {Migliori387，作者= {Migliori，G。B.和Eker，B。和Richardson，M。D.和Sotgiu，G。和Zellweger，j-p。以及Skrahina，A。和Ortmann，J。和Girardi，E。和Hoffmann，H。以及Besozzi，G。和Bevilacqua，N。和Kirsten，D。，以及Centis，R。和Lange，C。}，Editor = {，}，title = {lineZolid安全性，耐受性和疗效的回顾性TBNET评估多药耐药性结核病}，音量= {34}，number = {2}，pages = {387---393}，年= {2009}，earl = {2009}，doi = {10.1183/09031936.00009509}，出版商= {欧洲呼吸社会}，摘188bet官网地址要= {linezolid用于治疗患有多种药物（MDR）/广泛药物抗药性（XDR）的抗药性（XDR） - Tuberculculissis（TB）案例的患者缺乏有关其安全性，耐受性和功效的数据。我们进行了一项回顾性，非随机，无盲的观察性研究，评估了600 mg Q.D的LineZolid的安全性和耐受性。或B.I.D.在四个欧洲国家的MDR/XDR-TB治疗中。疗效评估比较了45个lineZolid处理的终点与110个linezolid非拘留案例的终点。在195名MDR/XDR-TB患者中，有85例用LineZolid治疗平均221天。 Of these, 35 (41.2\%) out of 85 experienced major side-effects attributed to linezolid (anaemia, thrombocytopenia and/or polyneuropathy), requiring discontinuation in 27 (77\%) cases. Most side-effects occurred after 60 days of treatment. Twice-daily administration produced more major side-effects than once-daily dosing (p = 0.0004), with no difference in efficacy found. Outcomes were similar in patients treated with/without linezolid (p = 0.8), although linezolid-treated cases had more first-line (p = 0.002) and second-line (p = 0.02) drug resistance and a higher number of previous treatment regimens (4.5 versus 2.3; p = 0.07). Linezolid 600 mg q.d. added to an individualised multidrug regimen may improve the chance of bacteriological conversion, providing a better chance of treatment success in only the most complicated MDR/XDR-TB cases. Its safety profile does not warrant use in cases for which there are other, safer, alternatives.}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/34/2/387}, eprint = {//www.qdcxjkg.com/content/34/2/387.full.pdf}, journal = {European Respiratory Journal} }